ESMO临床实践指南转移性非小细胞肺癌的诊断治Word文件下载.docx

1、 speakers0 bureau: Abbott Diagnostics, Roche, AstraZeneca, Eli Lilly, Pzer. SP has reported: consultancy/honoraria: Roche, Eli Lilly, AstraZeneca, Pzer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono, Daiichi Sankyo, Tesaro. DDR has declared no potential conicts of interest. references 1.

2、Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 6990. 2. Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet 2013; 382: 732741. 3. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality p

3、redictions for the year 2012. Ann Oncol 2012; 23: 10441052. 4. International Agency for Research on Cancer （IARC. http:/www.iarc.fr/ （23 May 2014, date last accessed. 5. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. Ann Oncol 2013; 24: 792800. 6. Wak

4、elee HA, Chang ET, Gomez SL et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25: 472478. 7. Edwards BK, Brown ML, Wingo PA et al. Annual report to the nation on the status of cancer, 19752002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97: 140714

5、27. 8. Toh CK, Gao F, Lim WT et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006; 22452251. 9. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Soci

6、ety: international multidisciplinary classication of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011; 8: 381385. 10. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 7

7、5ra26. 11. Kerr KM, Bubendorf L, Edelman MJ et al. 2nd ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014 June 17 epub ahead of print, doi:10.1093/annonc/mdu145. 12. Besse B, Adjei A, Baas P et al. 2nd ESMO Consensus Conference

8、 on Lung Cancer: non-small-cell lung cancer rst-line/second and further lines of treatment in advanced disease. Ann Oncol 2014; 14751484. 13. Rekhtman N, Paik PK, Arcila ME et al. Clarifying the spectrum of driver oncogene mutations in biomarker-veried squamous carcinoma of lung: lack of EGFR/KRAS a

9、nd presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18: 11671176. 14. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 16931703. 15. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patie

10、nts with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 42474253. 16. Wu Y, Li P, Zhang H et al. Diagnostic value of uorine 18 uorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cance

11、r 2013; 132: E37E47. 17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline （version 1.1. Eur J Cancer 2009; 45: 228247. 18. Baser S, Shannon VR, Eapen GA et al. Smoking cessation after diagnosis of lung cancer is associated with a benecial effect on performance status. Chest 2006; 130: 17841790. 19. Hughes AN, OBrien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib d